Pharmacologic treatment of schizophrenia. (Q33782631)

29 July 2017

1 reference

title

Pharmacologic treatment of schizophrenia. (English)

1 reference

29 July 2017

0 references

J M Kane

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

29 July 2017

published in

Biological Psychiatry

1 reference

29 July 2017

volume

46

1 reference

29 July 2017

issue

10

1 reference

29 July 2017

page(s)

1396-1408

1 reference

Decreased substance use in chronically psychotic patients treated with clozapine

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Association between clozapine response and allelic variation in 5-HT2A receptor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Patient response and resource management: another view of clozapine treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Continuous versus targeted medication in schizophrenic outpatients: outcome results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Clozapine: neuroleptic-induced EPS and tardive dyskinesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Overview: maintenance therapy in psychiatry: I. Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Depot antipsychotic drugs. Place in therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

The New York High-Risk Project: anhedonia, attentional deviance, and psychopathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Clozapine eligibility among state hospital patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

An Open Comparison of Clozapine and Risperidone in Treatment-Resistant Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Cognitive deficits in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

What are the functional consequences of neurocognitive deficits in schizophrenia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Intermittent vs maintenance medication in schizophrenia. Two-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Compliance issues in outpatient treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Risperidone in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Costs and benefits of two doses of fluphenazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Clozapine: is another view valid?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. The International Risperidone Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Very high dosage vs standard dosage fluphenazine in schizophrenia. A double-blind study of nonchronic treatment-refractory patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Dosage of haloperidol for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Relapse and Rehospitalization During Maintenance Treatment of Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Poor neuroleptic response in acutely exacerbated schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Unrecognized cocaine use among schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

A controlled dose comparison of haloperidol in newly admitted schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Haloperidol blood levels and clinical effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Cost of relapse in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900059-1

10.1016/S0006-3223(99)00059-1

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference